Systemic thrombolysis using alteplase in routine clinical practice resulted in 41% of acute ischemic stroke patients showing minimal or no disability at 1 year.
Observational (n=150)
Does systemic thrombolysis with alteplase improve functional outcomes at 1 year in patients with acute ischemic stroke in routine clinical practice?
Routine clinical use of alteplase for acute ischemic stroke in strict accordance with AHA guidelines yields 1-year functional outcomes comparable to those seen in randomized trials.
BACKGROUND AND PURPOSE: A recent placebo-controlled study provided evidence of a sustained benefit at 1 year from systemic thrombolysis in patients with acute ischemic stroke. The scope of the present study is to determine whether comparable results may be attained in everyday practice if current management guidelines are closely met. METHODS: Between March 1996 and July 1998, 150 consecutive patients with acute ischemic stroke were treated with systemic thrombolysis using alteplase, strictly in accordance with American Heart Association (AHA) guidelines. The patients were followed up for 12 months after treatment. RESULTS: Baseline characteristics and complication rates were comparable to those of the National Institute of Neurological Disorders and Stroke (NINDS) study, except for a somewhat younger age (mean 63 years) and lower National Institutes of Health Stroke Scale score (median 11). At 1 year, 41% of our patients showed minimal or no disability (Rankin scale score of 0 or 1), comparable to 41% in the NINDS rtPA group. The overall rate of recurrent stroke was 6.6% and the transient ischemic attack rate 3.3% at 1 year. Six patients (4%) died after the first 3 months, none of them due to recurrent stroke, and 5 had already been severely disabled at 3 months. CONCLUSIONS: These observations further encourage the routine use of rtPA for the treatment of acute ischemic stroke in strict accordance with the AHA guidelines.
Schmülling et al. (Sat,) conducted a observational in acute ischemic stroke (n=150). systemic thrombolysis using alteplase (rtPA) was evaluated on minimal or no disability (Rankin scale score of 0 or 1) at 1 year. Systemic thrombolysis using alteplase in routine clinical practice resulted in 41% of acute ischemic stroke patients showing minimal or no disability at 1 year.